Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.

Robocath, a France-based developer of a cardiovascular disease treatment system developer, raised €40m ($43.4m) in a series C round yesterday backed by Luxembourg CLIIF, an investment fund managed by the Tsinghua University-affiliated TUS-Holdings, Medical device manufacturer MicroPort Scientific led the round, which also included regional investment vehicles Go Capital, NCI and Normandie Participations, and national…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.